LXRX Company Profile and Key Details

LXRX has shown mixed momentum, gaining 11.02% over the past week and -7.75% over the past quarter, though year-to-date performance is up 13.91%. Short-term trend indicators are bearishly aligned (SMA20 11.4%, SMA50 14.43%, SMA200 27.48%). The stock’s 14-day RSI is 57.73 (neutral), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.03% below its high and over 428.91% above its low. Average 10-day trading volume of 8.29 million shares is significantly above the 3-month average of 3.11 million, indicating heightened recent market interest.

Lexicon Pharmaceuticals, Inc. has 363.40 million shares outstanding. The public float is 183.89 million shares, elevated short interest at 21.44% of float. This equals 27.91 million shares. The short ratio is 8.92 days. Institutional investors hold 72.93% of the float. Insiders own 1.17%. Artal International S.C.A. holds 78.63 million shares, Invus Advisors, L.L.C. has 50.86 million shares and Invus Public Equities, L.P. has 32.26 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Wall Street analysts project EPS growth of 28.96% annually over the next five years. The latest quarter delivered EPS of -$0.00. The next quarter is forecast at -$0.07. Next year's EPS is expected at $7.73. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $1.90. The high target offers 135.29% upside. The low target suggests -25.49% downside. The mean target is $3.88. This offers 52.16% upside. Lexicon Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 07, 2026, missed forecasts by -93.5%. The prior quarter beat by -42.86%. Over the last six quarters, Apple has recorded several small beats. These include -18.18% in March 06, 2025.

Our AI price prediction model suggests that Lexicon Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.49%, with price expected at $2.41 by July 10, 2026, within a range of $2.17 to $2.66 3-Month Outlook: Projected rise of 14.9%, reaching $2.93 by September 24, 2026, with a range of $2.88 to $2.98. 1-Year Outlook: Projected gain of 819.22%, with price at $23.44 by June 25, 2027, within a range of $20.85 to $30.97.

Lexicon Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.39. This means the shares are trading below this model’s fair value.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares are up 13.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Lexicon Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -35.22. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.91, suggesting 288.63% upside. Our AI forecast model points to short-term weakness (-5.49% over two weeks), a medium-term rise (14.9% over three months), and a longer-term gain (819.22% over one year), with expected trading ranges indicating moderate volatility.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) closed at $2.55 USD, gaining $0.26 (11.35%) from the previous close of $2.29. The stock is currently trading near its 52-week high $0.80 and $2.55. With a market capitalization of about $1.13 billion, Lexicon Pharmaceuticals, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.07). Key stats such as the average daily volume over the past year has been around 3.08 million shares, trading with heavier-than-usual volume. Headquartered in The Woodlands, TX, Lexicon Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael S. Exton, the company employs approximately 103 people and listed since April 07, 2000. Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds.

Lexicon Pharmaceuticals, Inc. trades at a P/E ratio of -35.22, slightly below the S&P 500 average, with a price-to-sales ratio of 16.04 and a price-to-book ratio of 4.96 trading at moderately above to book value. The P/FCF stands at -28.79, also below market averages.